Li Y, Wang Y Y, Xing K, Li S S
Department of Dermatology, the First Hospital of Jilin University, Changchun 130021, China.
Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi. 2022 Jun 20;38(6):574-579. doi: 10.3760/cma.j.cn501225-20220330-00108.
Pyoderma gangrenosum (PG) is a rare chronic inflammatory non-infectious skin dermatosis, and there is no clear treatment guideline for this disease at home and abroad. There are a variety of clinical treatment methods for PG, including local therapy and systemic application of glucocorticoids, immunosuppressants, intravenous immuno- globulin, and biologics. Glucocorticoids are the first-line drugs commonly used in clinical practice, and immunosuppressants can be used alone or in combination with glucocorticoids. In recent years, more and more evidence has shown that biologics are a new trend in the treatment of PG, mainly including tumor necrosis factor α inhibitors, interleukin-1 (IL-1) inhibitors, IL-12/23 inhibitors, IL-17 inhibitors, rituximab, and small molecular inhibitors. This article summarizes the current status and latest progress in the treatment of PG, hoping to provide clinicians with ideas for the treatment of PG.
坏疽性脓皮病(PG)是一种罕见的慢性炎症性非感染性皮肤病,国内外尚无针对该病的明确治疗指南。PG有多种临床治疗方法,包括局部治疗以及全身应用糖皮质激素、免疫抑制剂、静脉注射免疫球蛋白和生物制剂。糖皮质激素是临床常用的一线药物,免疫抑制剂可单独使用或与糖皮质激素联合使用。近年来,越来越多的证据表明生物制剂是PG治疗的新趋势,主要包括肿瘤坏死因子α抑制剂、白细胞介素-1(IL-1)抑制剂、IL-12/23抑制剂、IL-17抑制剂、利妥昔单抗和小分子抑制剂。本文总结了PG治疗的现状和最新进展,希望为临床医生治疗PG提供思路。